Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2923 Interim Analysis of Prospective Evaluation of the Management of Sporadic Nonfunctioning Asymptomatic Pancreatic Neuroendocrine Neoplasms ≤ 2 cm (ASPEN Study)

Introduction: Guidelines recommend a watchful strategy for small, incidental, nonfunctioning pancreatic neuroendocrine neoplasms (NF-PanNEN).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Partelli S

Authors: Partelli S, Zerbi A, Massironi S, Jin-Young J, Landoni L,

Keywords: small neuroendocrine pancreatic tumors, surveillance, surgery, follow-up,

#2903 Bone Metastases (BM) in Neuroendocrine Tumors (NET): Imaging Characteristics and Clinical Implications. A Single-Institution Experience

Introduction: The incidence of BM in NET is underestimated and there is no consensus on clinical features, diagnostic techniques, and treatment options.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Smiroldo V

Authors: Smiroldo V, Lania A, Pedicini V, Pepe G, Zerbi A,

Keywords: bone metastases, skeletal related event, survival, bisphosphonates, 68Ga-PET, 18FDG-PET, CT scan,

#2001 The Anticancer Mechanism of Metformin in Pancreatic Neuroendocrine Tumor Cells

Introduction: Metformin, a widely used antidiabetic drug, has been reported to display potent anticancer properties in various types of cancers. In P-NETs, aryl hydrocarbon receptor-interacting protein (AIP) acts as a tumor suppressor and is up-regulated by the somatostatin analog octreotide.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Lania A

Authors: Vitali E, Piccini S, Boemi I, Brambilla T, Zerbi A,

Keywords: GEP-NET, Metformin, AIP,

#1075 Filamin-A Is Required for Somatostatin Receptor 2 (SST2) Stabilization, Signaling and Angiogenesis Regulation in Gastroenteropancreatic Neuroendocrine Tumors

Introduction: Somatostatin receptor type 2 (SST2) is the main pharmacological target for GEP-NETs. A subset of patients is resistant to somatostatin analogs (SSa), although the molecular mechanisms responsible for resistance are poorly understood. Several studies identified cytoskeleton protein as determinant in receptor anchoring and signaling

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Vitali E, Cambiaghi V, Loiarro F, Zerbi A, Colombo P,

Keywords: FLNA, SST2, GEP-NET,

#985 Periampulary and Pancreatic Neuroendocrine Neoplasms with Duodenal Stromal Gastrointestinal Tumors in Patients with Type 1 Neurofibromatosis: Two Case Reports

Introduction: We describe two cases of neuroendocrine tumors (NETs) in patients with neurofibromatosis type 1 (NF1) associated with gastrointestinal stromal tumors (GISTs).

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Zerbi A

Authors: Ridolfi C, Gavazzi F, Spaggiari P, Carnaghi C, Lania A,

Keywords: pancreatic and ampullary neuroendocrine tumor, neurofibromatosis-1, GIST,